Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FATE

FATE - Fate Therapeutics Inc Stock Price, Fair Value and News

$1.170.00 (0.00%)
Market Closed

45/100

FATE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

45/100

FATE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FATE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FATE Price Action

Last 7 days

-12.0%

Last 90 days

1.7%

Trailing 12 Months

24.5%

FATE RSI Chart

FATE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FATE Valuation

Market Cap

136.0M

Price/Earnings (Trailing)

-1

Price/Sales (Trailing)

20.47

Price/Free Cashflow

-1.21

FATE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FATE Fundamentals

FATE Revenue

Revenue (TTM)

6.6M

Rev. Growth (Yr)

-26.4%

Rev. Growth (Qtr)

-21.37%

FATE Earnings

Earnings (TTM)

-136.3M

Earnings Growth (Yr)

37.92%

Earnings Growth (Qtr)

-0.38%

FATE Profitability

Return on Equity

-65.79%

Return on Assets

-42.74%

Free Cashflow Yield

-82.36%

FATE Investor Care

Shares Dilution (1Y)

1.45%

Diluted EPS (TTM)

-1.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202513.3M8.5M7.1M6.6M
20246.5M12.3M13.4M13.6M
2023136.9M119.3M106.2M63.5M
202263.1M68.3M69.0M96.3M
202140.1M48.0M54.7M55.8M
202010.6M13.2M18.3M31.4M
20196.3M8.1M9.5M10.7M
20184.1M4.1M4.1M4.7M
20174.1M4.1M4.1M4.1M
20163.8M4.5M4.5M4.4M
20150828.0K1.6M2.4M
20132.7M1.9M1.6M971.0K
20121.5M1.9M2.3M2.7M
20110001.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Fate Therapeutics Inc

FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
 CEO
 WEBSITEfatetherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES551

Fate Therapeutics Inc Frequently Asked Questions

FATE is the stock ticker symbol of Fate Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Fate Therapeutics Inc is 136.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, FATE's PE ratio (Price to Earnings) is -1 and Price to Sales (PS) ratio is 20.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FATE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Fate Therapeutics Inc has provided -0.038 (multiply by 100 for percentage) rate of return.